Programa de Pós-Graduação em Microbiologia, Parasitologia e Patologia, Departamento de Patologia, Universidade Federal do Paraná, Curitiba, Brazil.
Programa de Pós-Graduação em Biologia Celular e Molecular, Departamento de Biologia Celular, Universidade Federal do Paraná, Curitiba, Brazil.
Front Cell Infect Microbiol. 2020 Sep 23;10:417. doi: 10.3389/fcimb.2020.00417. eCollection 2020.
is a microaerophilic protozoan that is an important etiologic agent of diarrhea worldwide. There is evidence that under diverse conditions, the parasite is capable of shedding extracellular vesicles (EVs) which modulate the physiopathology of giardiasis. Here we describe new features of EV production, revealing its capacity to shed two different enriched EV populations: large (LEV) and small extracellular vesicles (SEV) and identified relevant adhesion functions associated with the larger population. Proteomic analysis revealed differences in proteins relevant for virulence and host-pathogen interactions between the two EV subsets, such as cytoskeletal and anti-oxidative stress response proteins in LEVS. We assessed the effect of two recently identified inhibitors of EV release in mammalian cells, namely peptidylarginine deiminase (PAD) inhibitor and cannabidiol (CBD), on EV release from . The compounds were both able to effectively reduce EV shedding, the PAD-inhibitor specifically affecting the release of LEVs and reducing parasite attachment to host cells . Our results suggest that LEVs and SEVs have a different role in host-pathogen interaction, and that treatment with EV-inhibitors may be a novel treatment strategy for recurrent giardiasis.
是一种微需氧的原生动物,是全世界腹泻的重要病因。有证据表明,在不同条件下,寄生虫能够脱落细胞外囊泡(EVs),从而调节贾第虫病的病理生理学。在这里,我们描述了 EV 产生的新特征,揭示了它能够脱落两种不同的富含 EV 的群体:大(LEV)和小细胞外囊泡(SEV),并确定了与较大群体相关的相关粘附功能。蛋白质组学分析显示,两种 EV 亚群之间与毒力和宿主-病原体相互作用相关的蛋白质存在差异,例如 LEVS 中的细胞骨架和抗氧化应激反应蛋白。我们评估了两种最近在哺乳动物细胞中发现的 EV 释放抑制剂,即肽基精氨酸脱亚氨酶(PAD)抑制剂和大麻二酚(CBD)对 的 EV 释放的影响。这两种化合物都能够有效地减少 EV 的脱落,PAD 抑制剂特别影响 LEVs 的释放并减少寄生虫与宿主细胞的附着。我们的结果表明,LEVs 和 SEVs 在宿主-病原体相互作用中具有不同的作用,并且使用 EV 抑制剂治疗可能是复发性贾第虫病的一种新的治疗策略。